Active Case Finding for Tuberculosis in India: A Syntheses of Activities and Outcomes Reported by the National Tuberculosis Elimination Programme.
active case finding
diagnostic algorithm
number needed to screen
tuberculosis
Journal
Tropical medicine and infectious disease
ISSN: 2414-6366
Titre abrégé: Trop Med Infect Dis
Pays: Switzerland
ID NLM: 101709042
Informations de publication
Date de publication:
30 Nov 2021
30 Nov 2021
Historique:
received:
27
09
2021
revised:
16
10
2021
accepted:
21
10
2021
entrez:
23
12
2021
pubmed:
24
12
2021
medline:
24
12
2021
Statut:
epublish
Résumé
India launched a national community-based active TB case finding (ACF) campaign in 2017 as part of the strategic plan of the National Tuberculosis Elimination Programme (NTEP). This review evaluated the outcomes for the components of the ACF campaign against the NTEP's minimum indicators and elicited the challenges faced in implementation. We supplemented data from completed pretested data proformas returned by ACF programme managers from nine states and two union territories (for 2017-2019) and five implementing partner agencies (2013-2020), with summary national data on the state-wise ACF outcomes for 2018-2020 published in annual reports by the NTEP. The data revealed variations in the strategies used to map and screen vulnerable populations and the diagnostic algorithms used across the states and union territories. National data were unavailable to assess whether the NTEP indicators for the minimum proportions identified with presumptive TB among those screened (5%), those with presumptive TB undergoing diagnostic tests (>95%), the minimum sputum smear positivity rate (2% to 3%), those with negative sputum smears tested with chest X-rays or CBNAAT (>95%) and those diagnosed through ACF initiated on anti-TB treatment (>95%) were fulfilled. Only 30% (10/33) of the states in 2018, 23% (7/31) in 2019 and 21% (7/34) in 2020 met the NTEP expectation that 5% of those tested through ACF would be diagnosed with TB (all forms). The number needed to screen to diagnose one person with TB (NNS) was not included among the NTEP's programme indicators. This rough indicator of the efficiency of ACF varied considerably across the states and union territories. The median NNS in 2018 was 2080 (interquartile range or IQR 517-4068). In 2019, the NNS was 2468 (IQR 1050-7924), and in 2020, the NNS was 906 (IQR 108-6550). The data consistently revealed that the states that tested a greater proportion of those screened during ACF and used chest X-rays or CBNAAT (or both) to diagnose TB had a higher diagnostic yield with a lower NNS. Many implementation challenges, related to health systems, healthcare provision and difficulties experienced by patients, were elicited. We suggest a series of strategic interventions addressing the implementation challenges and the six gaps identified in ACF outcomes and the expected indicators that could potentially improve the efficacy and effectiveness of community-based ACF in India.
Identifiants
pubmed: 34941662
pii: tropicalmed6040206
doi: 10.3390/tropicalmed6040206
pmc: PMC8705069
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
ERJ Open Res. 2020 May 04;6(2):
pubmed: 32391397
Tuberc Res Treat. 2020 Jan 24;2020:9746329
pubmed: 32047666
PLoS One. 2015 May 22;10(5):e0127725
pubmed: 26001190
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Trop Med Infect Dis. 2020 Nov 30;5(4):
pubmed: 33265972
Lancet Infect Dis. 2010 Feb;10(2):93-102
pubmed: 20113978
Int J Tuberc Lung Dis. 2013 Apr;17(4):432-46
pubmed: 23485377
Trop Med Int Health. 2015 Sep;20(9):1128-1145
pubmed: 25943163
PLoS One. 2019 Jul 2;14(7):e0210919
pubmed: 31265458
BMJ. 2018 May 16;361:k1079
pubmed: 29769210
Lancet Infect Dis. 2016 Sep;16(9):1045-1051
pubmed: 27289387
Eur Respir J. 2013 Jan;41(1):140-56
pubmed: 22936710
Glob Health Action. 2018;11(1):1494897
pubmed: 30173603
PLoS One. 2016 Feb 10;11(2):e0148293
pubmed: 26863617
Cochrane Database Syst Rev. 2017 Nov 28;11:CD011432
pubmed: 29182800
Public Health Action. 2017 Dec 21;7(4):307
pubmed: 29344442
PLoS One. 2018 Dec 18;13(12):e0209290
pubmed: 30562401
PLoS One. 2019 Mar 13;14(3):e0213345
pubmed: 30865730
BMC Infect Dis. 2020 Jan 31;20(1):96
pubmed: 32005136
N Engl J Med. 2019 Oct 3;381(14):1347-1357
pubmed: 31577876
Indian J Med Res. 2015 May;141(5):614-23
pubmed: 26139779
Bull World Health Organ. 2018 Aug 1;96(8):522-530
pubmed: 30104792
Int J Tuberc Lung Dis. 2005 Oct;9(10):1072-82
pubmed: 16229217
PLoS Med. 2020 Dec 2;17(12):e1003456
pubmed: 33264288
Int J Mycobacteriol. 2016 Dec;5(4):374-378
pubmed: 27931676
Lung India. 2020 Jan-Feb;37(1):45-52
pubmed: 31898620
Trop Med Infect Dis. 2020 Jun 18;5(2):
pubmed: 32570828
Clin Microbiol Rev. 2018 Jul 18;31(4):
pubmed: 30021818
PLoS One. 2019 Feb 22;14(2):e0212264
pubmed: 30794595
PLoS Med. 2011 Nov;8(11):e1001120
pubmed: 22087078
Int J Tuberc Lung Dis. 2005 Nov;9(11):1183-203
pubmed: 16333924
Trop Med Infect Dis. 2019 Dec 21;5(1):
pubmed: 31877818
BMJ. 2020 Jan 16;368:l6890
pubmed: 31948937
Indian J Tuberc. 2019 Jan;66(1):170-177
pubmed: 30878064